Chromosome 4 News and Research

RSS

Humans normally have 46 chromosomes in each cell, divided into 23 pairs. Two copies of chromosome 4, one copy inherited from each parent, form one of the pairs. Chromosome 4 spans more than 191 million DNA building blocks (base pairs) and represents more than 6 percent of the total DNA in cells.

Identifying genes on each chromosome is an active area of genetic research. Because researchers use different approaches to predict the number of genes on each chromosome, the estimated number of genes varies. Chromosome 4 likely contains between 1,300 and 1,600 genes.

Genes on chromosome 4 are among the estimated 20,000 to 25,000 total genes in the human genome.

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Cancer Research UK scientists have discovered cancer-blocking activity for genes carried on chromosome 21 - an extra copy of which is carried by people with Down's syndrome, reveals research published in Nature.

11 Jun 2010

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Scientists have pinpointed key changes to the telomeres in the cells of leukaemia patients which could play a crucial role in the earliest stages of the disease, according to research published online in the journal Blood.

11 Jun 2010

Copy number variants may cause autism: Study

An international consortium of researchers from more than 70 universities, including the University of Utah, has reported that a study of nearly 2,300 people supports the growing consensus that autism is caused in part by rare genetic changes called copy number variants (CNVs).

10 Jun 2010

Autism is caused in part by CNVs: Study

10 Jun 2010

Research findings hold promise for debilitating emotional symptoms of FXS

The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.

9 Jun 2010

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

A new study pinpoints the genetic changes that enable Tibetans to thrive at altitudes where others get sick.

8 Jun 2010

$Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL$

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences Inc.,, today announced complete data from its pivotal, Phase 2 RALLY clinical trial for Marqibo® (vincristine sulfate liposome injection) for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Results from the RALLY trial demonstrated compelling evidence of single-agent, anti-leukemic activity in an advanced, heavily pre-treated, adult ALL population.

8 Jun 2010

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

The Prostate Cancer Foundation announced today that researchers at the University of Michigan Comprehensive Cancer Center have discovered the RAF oncogene that drives fatal melanomas may also drive the aggressive forms of prostate cancer in the clinic.

8 Jun 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Researchers identify region of DNA that may contain gene linked to progression, spread of bowel cancer

Scientists have identified a region of DNA that appears to be involved in the development of pre-cancerous bowel growths (polyps) and that may contain a gene involved in the progression of bowel cancer.

4 Jun 2010

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.

2 Jun 2010

Scientists discover key mechanism of cancer cells

Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells.

2 Jun 2010

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Scientists from Singapore, China and USA have identified three new susceptibility genes in a genome-wide association study of nasopharyngeal carcinoma (NPC). The study, led by the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, identified genetic risk factors of NPC that advance the understanding of the important role played by host genetic variation in influencing the susceptibility to this cancer.

31 May 2010

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

Writing the latest pages of an anthropological mystery, scientists propose in this month's Archives of Neurology that it is highly possible that Auguste Deter, the first identified Alzheimer disease patient, carried the N141I presenilin-2 mutation—the same one as in present-day U.S. families descended from German emigrants who settled near the river Volga in Russia.

29 May 2010

Researchers discover genetic variant that raises risk of CHD

Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the common variation in the genes that give rise to it. Now genetics and cardiology researchers, two of them brothers, have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease.

27 May 2010

PDGFRA gene may lead to effective treatments for paediatric high grade glioma: Study

Scientists have discovered a gene that could lead to more effective treatments for a form of childhood brain cancer called paediatric high grade glioma.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

JCVI researchers construct first self-replicating, synthetic bacterial cell

Researchers at the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, published results today describing the successful construction of the first self-replicating, synthetic bacterial cell. The team synthesized the 1.08 million base pair chromosome of a modified Mycoplasma mycoides genome.

21 May 2010

Chromosome 4 News and Research

Further Reading

UK scientists discover cancer-blocking activity in Down's syndrome chromosome

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Copy number variants may cause autism: Study

Autism is caused in part by CNVs: Study

Research findings hold promise for debilitating emotional symptoms of FXS

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Researchers identify region of DNA that may contain gene linked to progression, spread of bowel cancer

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Scientists discover key mechanism of cancer cells

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Circumstantial evidence suggests first identified Alzheimer disease patient carried N141I presenilin-2 mutation

Researchers discover genetic variant that raises risk of CHD

PDGFRA gene may lead to effective treatments for paediatric high grade glioma: Study

Study explores genetic imbalances that give rise to childhood brain tumors

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

JCVI researchers construct first self-replicating, synthetic bacterial cell

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News